Two Phase 3 Studies of the Triple Combination of VX-445, Tezacaftor and Ivacaftor Met Primary Endpoint of Improvement in Lung Function (ppFEV1) in People with Cystic Fibrosis Read more
NovaGo Therapeutics Raises CHF 10 Million to Develop Regenerative Anti-Nogo Therapy for Stroke Read more